Streptococcus pneumoniae: Caractéristiques et Diagnostic

Streptococcus Pneumoniae: An Exhaustive Overview

Streptococcus pneumoniae, commonly known as pneumococcus, is a Gram-positive, lancet-shaped diplococcus that is a significant human pathogen. It is a leading cause of pneumonia, meningitis, otitis media, and other invasive diseases globally. This organism is part of the normal flora of the upper respiratory tract but can cause severe infections, particularly in immunocompromised individuals, the elderly, and young children. Understanding its characteristics, virulence factors, pathogenicity, diagnosis, treatment, and prevention is crucial for effective clinical management and public health strategies.

Bacterial Taxonomy and General Characteristics

Streptococcus pneumoniae belongs to the phylum Firmicutes, class Bacilli, order Lactobacillales, family Streptococcaceae, and genus Streptococcus. This classification places it within a broad group of Gram-positive bacteria. The organism exhibits several defining characteristics:

• Morphology: It typically appears as Gram-positive, lancet-shaped diplococci (paired cocci), although short chains can sometimes be observed. Individual cells range from 0.5 to 1.25 μm in diameter.
• Habitat: Its primary habitat is the human upper respiratory tract, particularly the nasopharynx, where it frequently colonizes as a commensal without causing symptoms.
• Capsule: A prominent feature is its polysaccharide capsule, which is the major virulence factor and is serotype-specific. Over 90 distinct capsular serotypes have been identified, each with varying degrees of invasiveness and pathogenicity.
• Colony Appearance: On blood agar, S. pneumoniae typically exhibits α-hemolysis (partial hemolysis), characterized by a greenish discoloration around the colonies due to the reduction of hemoglobin. Encapsulated strains produce smooth, moist, mucoid, and often dome-shaped colonies with a concave center upon aging.
• Biochemical Tests:
  • Catalase & Oxidase Test: Both are negative, a key characteristic that distinguishes it from staphylococci.
  • Bile Solubility: Soluble in 2–10% sodium deoxycholate (bile), which helps differentiate it from other α-hemolytic streptococci like Streptococcus viridans.
  • Optochin Sensitivity: Sensitive to optochin (ethylhydrocupreine hydrochloride), a diagnostic test used to identify S. pneumoniae.
• Growth Requirements: It is a facultative anaerobe, meaning it can grow in both the presence and absence of oxygen. It grows well on blood agar, and fastidious strains may require enriched media, often with 5-10% CO2 for enhanced growth.

Antigenic Structure and Virulence Factors

The pathogenicity of S. pneumoniae is primarily mediated by its diverse array of virulence factors, which enable it to colonize, evade host defenses, and cause tissue damage.

Antigenic Structure:

• C Polysaccharide: The cell wall contains a common antigen known as C polysaccharide. This antigen reacts with C-reactive protein (CRP) (a β-globulin) in human serum, leading to precipitate formation. CRP levels rise significantly during inflammation and infection, making it a useful clinical marker for bacterial infections, including pneumococcal disease.
• Capsular Polysaccharide: The most critical antigenic component is the capsular polysaccharide. Its unique structure is the basis for capsular typing (serotyping), which is detected using specific antisera in the Neufeld test (Quellung reaction). The capsule's chemical composition determines the serotype, with over 90 known types.

Key Virulence Factors:

The capsule is the primary virulence factor, but pneumococcal proteins and other enzymes also play crucial roles.

Virulence Factor	Type / Location	Role in Disease
Capsule	Polysaccharide capsule	Anti-phagocytic; interferes with phagocytosis by inhibiting the binding of complement C3b to the bacterial surface. It protects the bacteria from immune clearance and is the major determinant of serotype.
Pneumolysin (PLY)	Cytotoxin, released from bacteria	A pore-forming toxin that lyses host cells (e.g., erythrocytes, phagocytes), damages tissues, activates the complement system, and triggers inflammatory responses.
Autolysin (LytA)	Enzyme in cell wall	Causes bacterial autolysis, leading to the release of pneumolysin, DNA, teichoic acids, and other cell wall components, which further contribute to inflammation and tissue damage.
Surface Proteins (PspA, PspC)	Cell surface	PspA (Pneumococcal surface protein A) and PspC (Pneumococcal surface protein C) are involved in immune evasion by inhibiting complement deposition and binding to host factors like lactoferrin. They also aid in adherence to host cells.
Teichoic and Lipoteichoic Acids	Cell wall	Components of the cell wall that promote adherence to epithelial cells and trigger strong inflammatory responses, contributing to tissue damage.
Neuraminidase (NanA, NanB)	Enzyme	Cleaves sialic acids from host glycoconjugates, which aids in colonization of the respiratory tract by uncovering binding sites and facilitating bacterial spread.
Hyaluronidase	Enzyme	Breaks down hyaluronic acid, a component of connective tissue, allowing the bacteria to spread more easily through tissues and invade deeper sites.
IgA1 Protease	Enzyme	Cleaves secretory IgA (sIgA), the primary antibody found on mucosal surfaces. This action helps the bacteria evade mucosal immunity and colonize the respiratory tract more effectively.
Hemolysin	Toxin	Another term often used to describe toxins like pneumolysin that can lyse red blood cells, contributing to tissue damage and iron acquisition.

Electron micrographs highlight the impact of muralytic enzymes on pneumococci. For instance, treatment with CbpD-B6 can cause significant damage to the cell wall, indicating the cell wall's vulnerability and the importance of structural integrity for bacterial survival.

Pathogenicity and Clinical Manifestations

S. pneumoniae typically begins its pathogenic journey by colonizing the nasopharynx asymptomatically. However, under certain conditions, such as a preceding viral infection (e.g., influenza) or an immunocompromised state, the bacteria can overcome host defenses and cause disease.

Clinical Manifestations include:

• Pneumonia: The most common severe infection. It often presents as lobar pneumonia, characterized by fever, chills, cough productive of rust-colored sputum, and pleuritic chest pain.
• Otitis Media: A frequent infection in children under 3 years old, causing ear pain, fever, and sometimes hearing loss.
• Sinusitis: Inflammation of the paranasal sinuses, leading to facial pain, headache, and nasal discharge.
• Bacteremia: Presence of bacteria in the bloodstream, which can lead to severe systemic infection and spread to other organs.
• Meningitis: A life-threatening infection of the meninges (membranes surrounding the brain and spinal cord). Symptoms include high fever, severe headache, stiff neck (nuchal rigidity), photophobia, and altered mental status. It can result in permanent neurological damage or death.
• Sepsis: A severe, often life-threatening systemic response to infection, leading to organ dysfunction.
• Disseminated Organ Damage: In severe cases, particularly with bacteremia, S. pneumoniae can spread to and damage various organs, including the heart (e.g., endocarditis), joints (e.g., septic arthritis), and bone (e.g., osteomyelitis).

Laboratory Diagnosis

Accurate and rapid diagnosis of pneumococcal infections is essential for timely treatment. Various laboratory methods are employed for identification.

1. Microscopic Examination:

• Specimens: Collected based on the suspected site of infection, including sputum (for pneumonia), pleural fluid (for empyema), blood (for bacteremia/sepsis), and cerebrospinal fluid (CSF) (for meningitis).
• Gram Stain: A direct Gram stain of clinical specimens reveals Gram-positive cocci, typically arranged as diplococci or in short chains. The lancet shape is a characteristic feature.

2. Culture:

• Media: S. pneumoniae is cultured on enriched media such as blood agar (e.g., 5% sheep blood Tryptone Soy Agar) or chocolate agar. Growth is enhanced in an atmosphere with 5-10% CO2 at 37°C.
• Colony Morphology: Colonies are typically round, shiny, moist, and often mucoid, especially with encapsulated strains. They show α-hemolysis on blood agar. Over time, encapsulated colonies may develop a depressed center, giving them a "draughtsman" or "umbilicated" appearance.

3. Biochemical Identification (Rapid Tests):

Several biochemical and rapid immunological tests aid in differentiating S. pneumoniae from other α-hemolytic streptococci.

Characteristic	S. pneumoniae	Other α-hemolytic Streptococci (e.g., S. mitis)
Hemolysis type	α (partial)	α (partial)
Catalase test	Negative	Negative
Oxidase test	Negative	Negative
Bile solubility	Positive (soluble)	Negative (insoluble)
Optochin susceptibility	Sensitive (zone of inhibition)	Resistant
Hydrolysis of Hippurate	–	–
PYR test	–	–
CAMP test	–	–
Leucine aminopeptidase	+	—
Bile esculin	–	–
Growth in 6.5% NaCl	–	–
Vancomycin susceptibility	S	S
Bacitracin susceptibility	S	S
SMZ (Sulfamethoxazole) susceptibility	S	S

Immunochromatographic Tests: Rapid antigen detection tests, such as the BinaxNOW S. pneumoniae antigen card, detect pneumococcal C polysaccharide in respiratory specimens (e.g., urine, CSF, sputum). These tests offer rapid results and can be positive even after antibiotic treatment has begun, when bacterial cultures may be negative. A positive test result is indicated by the presence of both a control line and a test line.

4. Molecular Tests:

Molecular methods offer high sensitivity and specificity, particularly useful when cultures are difficult to obtain or when antibiotic therapy has initiated.

• PCR (Polymerase Chain Reaction): Detects pneumococcal DNA directly from clinical specimens (blood, CSF, sputum). Common gene targets include:
  • lytA gene (encoding autolysin)
  • ply gene (encoding pneumolysin)
  • cps genes (encoding capsular polysaccharide synthesis proteins)

  PCR is advantageous for its high sensitivity and specificity and its utility when antibiotic use might lead to negative cultures.

• Real-Time PCR (qPCR): A more advanced PCR technique that quantifies bacterial load in real-time, offering faster and more accurate results than conventional PCR.
• Other Molecular Methods:
  • Loop-mediated Isothermal Amplification (LAMP): A rapid, cost-effective nucleic acid amplification technique.
  • Microarray or Next-Generation Sequencing: Primarily used in research settings for strain characterization and epidemiological studies.

Treatment and Prevention

Treatment:

Treatment for S. pneumoniae infections depends on the severity of the infection and the antibiotic susceptibility of the strain. Resistance to penicillin and other antibiotics is a growing concern.

Infection / Severity	First-line Antibiotic	Alternative
Mild community-acquired pneumonia / Otitis media / Sinusitis	Amoxicillin	Macrolides (Azithromycin, Clarithromycin) if penicillin-allergic
Severe pneumonia / Bacteremia	IV Penicillin G or Ampicillin (if susceptible)	IV Ceftriaxone or Cefotaxime for resistant strains
Meningitis	High-dose IV Ceftriaxone or Cefotaxime	Add Vancomycin empirically until susceptibility confirmed (due to high mortality risk and potential resistance)
Penicillin-resistant strains	Ceftriaxone or Cefotaxime	Fluoroquinolones (Levofloxacin, Moxifloxacin) in adults
Supportive care	Oxygen therapy, intravenous fluids, pain relief, and monitoring for sepsis and organ dysfunction.

Prevention (Prophylaxis):

Vaccination is the most effective strategy for preventing pneumococcal disease.

• Pneumococcal Vaccines:
  • Pneumococcal Conjugate Vaccines (PCVs): Examples include Prevenar 13 (PCV13). These vaccines contain purified capsular polysaccharides from common pathogenic serotypes conjugated to a protein carrier (e.g., diphtheria toxoid). The conjugation makes the vaccine T-cell dependent, leading to a stronger and longer-lasting immune response, and induces immunologic memory, which is crucial for protecting infants and young children. PCV13 protects against 13 serotypes and is included in national vaccination programs, typically administered in three doses starting from 2 months of age.
  • Pneumococcal Polysaccharide Vaccines (PPSVs): An example is PPSV23, which contains 23 capsular polysaccharides. These vaccines are T-cell independent and primarily used in adults (especially those over 65) and individuals with certain underlying health conditions.